Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Ophthalmic Plast Reconstr Surg. 2010 May-Jun;26(3):185-9. doi: 10.1097/IOP.0b013e3181ba75e6.
To report a series of adults with orbital soft tissue sarcoma treated with various combinations of chemotherapy, radiation therapy, and surgery and to report on the efficacy of neoadjuvant therapy in these patients.
The medical records of adults who presented to our institution with orbital soft tissue sarcoma between 2003 and 2008 were reviewed. Outcome measures reviewed included response to chemotherapy, type of surgery, length of follow-up, visual acuity at last follow-up, local recurrence, distant metastasis, disease-free interval, and death.
Thirteen patients were identified. Nine had primary orbital lesions, 1 had a locally recurrent orbital lesion, 1 had a secondary tumor extending from the paranasal sinuses, and 2 had metastases in the orbit from primary tumors at other sites. Six patients (46%) had chemotherapy, and 10 (77%) had external-beam radiation therapy; 12 patients (92%) underwent surgical resection. The mean follow-up time for all patients was 26 months (range, 2 months -7 years). Three patients (23%) received preoperative chemotherapy with or without radiation therapy. Two of these patients underwent globe-preserving surgery, and 1 required an orbital exenteration due to the extent of disease even after chemoreduction.
Adults with orbital sarcomas may benefit from preoperative chemotherapy with or without radiation therapy. Multidisciplinary care with involvement of medical oncologists and radiation oncologists who are familiar with sarcoma chemotherapy and radiation may benefit these patients.
报告一系列接受不同化疗、放疗和手术联合治疗的成人眼眶软组织肉瘤患者,并报告这些患者新辅助治疗的疗效。
回顾了 2003 年至 2008 年期间在我院就诊的成人眼眶软组织肉瘤患者的病历。评估的结果包括化疗反应、手术类型、随访时间、末次随访时的视力、局部复发、远处转移、无病间隔和死亡。
共确定了 13 名患者。9 名患者有原发性眼眶病变,1 名患者有局部复发性眼眶病变,1 名患者有来自副鼻窦的继发性肿瘤,2 名患者有来自其他部位原发性肿瘤的眼眶转移。6 名患者(46%)接受了化疗,10 名患者(77%)接受了外照射放疗;12 名患者(92%)接受了手术切除。所有患者的平均随访时间为 26 个月(范围 2 个月至 7 年)。3 名患者(23%)接受了术前化疗联合或不联合放疗。这 2 名患者接受了保眼球手术,1 名患者由于疾病范围广泛,即使在化学减容后仍需要进行眼眶内容剜除术。
成人眼眶肉瘤患者可能受益于术前化疗联合或不联合放疗。多学科治疗,包括熟悉肉瘤化疗和放疗的肿瘤内科医生和放疗科医生的参与,可能对这些患者有益。